Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Fledgling Cameras for 2024: Ideal for New Photographic artists - 2Tanzania president remorseful over internet shutdown on election day
- 3Humpback whale stranded on Germany's Baltic coast frees itself
- 4Saudi Arabia says it intercepted 7 missiles, debris falls near energy facilities
- 5Dave Coulier reveals he has tongue cancer, his 2nd diagnosis in a year, after beating non-Hodgkin lymphoma
- UN warns civil liberties under threat due to war in Middle East
- A definitive Handbook for Securities exchange Money management
- Inconceivable Spots To Stargaze All over The Planet
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024
- It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar
- Best Exciting ride: Which One Rushes You the Most?
- What to know about voluntary chocolate recall
- Investigating Inside Plan and Home Style: Change Your Residing Space
